Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.71 |
| ▸ | LMNA | P02545 | 5/20 | 0.71 |
| ▸ | TP53 | P04637 | 3/20 | 0.71 |
| ▸ | RAB9A | P51151 | 4/20 | 0.61 |
| ▸ | HTT | P42858 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | NPC1 | O15118 | 3/20 | 0.61 |
| ▸ | HPGD | P15428 | 3/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.61 |
| ▸ | MEN1 | O00255 | 6/20 | 0.61 |
| ▸ | MAPT | P10636 | 4/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.61 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.59 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.59 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL579469 | 0.86 | OPRM1 (0.67) | SMN1; SMN2RAB9ANPC1HPGDKMT2A | |
| SCHEMBL580054 | 0.85 | OPRM1 (0.55) | SMN1; SMN2LMNATP53RAB9AHTT | |
| SCHEMBL5739389 | 0.84 | MEN1 (0.51) | SMN1; SMN2LMNATP53RAB9AHTT | |
| SCHEMBL579507 | 0.84 | OPRM1 (0.56) | SMN1; SMN2LMNATP53ALDH1A1KMT2A | |
| SCHEMBL2575722 | 0.83 | SMN1; SMN2 (0.91) | SMN1; SMN2LMNATP53RAB9AHTT | |
| SCHEMBL580191 | 0.82 | GAA (0.58) | SMN1; SMN2LMNATP53RAB9AHTT | |
| SCHEMBL579606 | 0.82 | OPRM1 (0.65) | ALDH1A1L3MBTL1KMT2AMEN1NPSR1 | |
| SCHEMBL5739394 | 0.81 | KMT2A (0.48) | SMN1; SMN2LMNATP53RAB9AHTT | |
| SCHEMBL579511 | 0.81 | OPRM1 (0.61) | SMN1; SMN2LMNARAB9AHTTALDH1A1 | |
| SCHEMBL579444 | 0.81 | OPRM1 (0.60) | SMN1; SMN2RAB9ANPC1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1735268-B1 | OPIOID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2012-02-15 | — | — | EP | claimed |
| US-20110105571-A1 | Opioid Receptor Antagonists | ELI LILLY AND COMPANY (US) | 2011-05-05 | — | — | US | disclosed |
| US-7902372-B2 | Therapy for obesity; using a secondary amino compound | ELI LILLY AND COMPANY (US) | 2011-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105571-A1 | Opioid Receptor Antagonists | OPRD1, OPRM1, OPRK1 | SMN1; SMN2 2464/4885LMNA 3778/4885TP53 4829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.